Patents by Inventor Sihem Cheloufi
Sihem Cheloufi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240102010Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: ApplicationFiled: August 4, 2023Publication date: March 28, 2024Applicant: Cold Spring Harbor LaboratoryInventors: Gregory J. Hannon, Sihem Cheloufi
-
Patent number: 11753641Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: GrantFiled: February 8, 2021Date of Patent: September 12, 2023Assignee: Cold Spring Harbor LaboratoryInventors: Gregory J. Hannon, Sihem Cheloufi
-
Publication number: 20210254064Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: ApplicationFiled: February 8, 2021Publication date: August 19, 2021Applicant: Cold Spring Harbor LaboratoryInventors: Gregory J. Hannon, Sihem Cheloufi
-
Publication number: 20200048633Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: ApplicationFiled: May 6, 2019Publication date: February 13, 2020Applicant: Cold Spring Harbor LaboratoryInventors: Gregory J. Hannon, Sihem Cheloufi
-
Patent number: 10329562Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Agog because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: GrantFiled: March 6, 2017Date of Patent: June 25, 2019Assignee: COLD SPRING HARBOR LABORATORYInventors: Gregory J. Hannon, Sihem Cheloufi
-
Publication number: 20180327745Abstract: Provided herein are methods for performing cellular reprogramming that include treatment of somatic cells with an inhibitor of CAF-1, Sumo2, Nutd21, or combinations thereof prior to or during a reprogramming procedure. Such inhibitors can improve both the speed and efficiency of cellular reprogramming. Inhibitors of the CAF-1 complex can also be used in the treatment of cancer.Type: ApplicationFiled: July 24, 2018Publication date: November 15, 2018Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Konrad HOCHEDLINGER, Sihem CHELOUFI
-
Patent number: 10059945Abstract: Provided herein are methods for performing cellular reprogramming that include treatment of somatic cells with an inhibitor of CAF-1, Sumo2, Nutd21, or combinations thereof prior to or during a reprogramming procedure. Such inhibitors can improve both the speed and efficiency of cellular reprogramming. Inhibitors of the CAF-1 complex can also be used in the treatment of cancer.Type: GrantFiled: February 27, 2017Date of Patent: August 28, 2018Assignee: The General Hospital CorporationInventors: Konrad Hochedlinger, Sihem Cheloufi, Marti Anne Borkent
-
Publication number: 20170342410Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Agog because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: ApplicationFiled: March 6, 2017Publication date: November 30, 2017Applicant: Cold Spring Harbor LaboratoryInventors: Gregory J. Hannon, Sihem Cheloufi
-
Publication number: 20170175120Abstract: Provided herein are methods for performing cellular reprogramming that include treatment of somatic cells with an inhibitor of CAF-1, Sumo2, Nutd21, or combinations thereof prior to or during a reprogramming procedure. Such inhibitors can improve both the speed and efficiency of cellular reprogramming. Inhibitors of the CAF-1 complex can also be used in the treatment of cancer.Type: ApplicationFiled: February 27, 2017Publication date: June 22, 2017Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Konrad HOCHEDLINGER, Sihem CHELOUFI, Marti Anne BORKENT
-
Patent number: 9624494Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: GrantFiled: February 24, 2015Date of Patent: April 18, 2017Assignee: COLD SPRING HARBOR LABORATORYInventors: Gregory J. Hannon, Sihem Cheloufi
-
Publication number: 20150197749Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: ApplicationFiled: February 24, 2015Publication date: July 16, 2015Applicant: Cold Spring Harbor LaboratoryInventors: Gregory J. Hannon, Sihem Cheloufi
-
Patent number: 8993532Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: GrantFiled: April 22, 2011Date of Patent: March 31, 2015Assignee: Cold Spring Harbor LaboratoryInventors: Gregory J. Hannon, Sihem Cheloufi
-
Publication number: 20130179999Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: ApplicationFiled: April 22, 2011Publication date: July 11, 2013Applicant: COLD SPRING HARBOR LABORATORYInventors: Gregory J. Hannon, Sihem Cheloufi
-
Patent number: 8273871Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: GrantFiled: October 4, 2011Date of Patent: September 25, 2012Assignee: Cold Spring Harbir LaboratoryInventors: Gregory J. Hannon, Sihem Cheloufi
-
Publication number: 20120021516Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: ApplicationFiled: October 4, 2011Publication date: January 26, 2012Inventors: Gregory J. Hannon, Sihem Cheloufi
